Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Johnson & Johnson (J&J) has agreed to pay almost $9bn (£7.2bn) to settle tens of thousands of lawsuits alleging its talc caused cancer.

Johnson & Johnson agrees to pay $8.9bn to settle claims that talc caused cancer

Johnson & Johnson (NYSE:JNJ) has offered nearly US$9bn to settle thousands of lawsuits alleging its baby powder and talc products cause cancer. It had initially proposed a US$2bn pay-out, attempting to quash some 40,000 lawsuits, but raised the figure almost five-fold to US$8.9bn, suggesting that 60,000 claimants already supported the new offer.

Johnson & Johnson offers billions to settle baby powder lawsuits

The conglomerate was prevented from offloading its liability to a subsidiary that immediately declared bankruptcy

Johnson & Johnson agrees to pay $8.9bn over alleged cancer-causing talc claims

Johnson & Johnson is trying once again to use the bankruptcy courts to settle tens of thousands of cases that claim its talc products cause cancer. The pharmaceutical company is now willing to pay $8.9 billion to plaintiffs over 25 years.

Johnson & Johnson is again trying to use bankruptcy to settle talc cases for $8.9 billion

ST LOUIS--(BUSINESS WIRE)--Lawyers representing tens of thousands of plaintiffs have successfully reached resolution with Johnson & Johnson (NYSE: JNJ) after years of the pharmaceutical giant scheming to avoid responsibility for its cancer-causing talcum powder products. J&J has agreed to pay $8.9 billion into a bankruptcy trust to compensate both current and future victims of talc-related cancers. According to lawyers familiar with the terms, that amount is set to increase to $12.

Nachawati Law Group: Victims, Johnson & Johnson Reach Multibillion-Dollar Resolution of Talc-Cancer Lawsuits

In a press release, the company said that its subsidiary, LTL Management, would refile for bankruptcy protection.

Johnson & Johnson to Settle Talc Claims for $8.9 Billion. The Stock Is Jumping.

A unit of the health-products company is also refiling for bankruptcy protection to seek approval for the settlement plan.

Johnson & Johnson Proposes Paying $9 Billion to Settle Talc Lawsuits

Johnson & Johnson said it would pay an $8.9 billion settlement over claims that its talc-based baby powder caused cancer.

J&J will pay $8.9 billion to settle claims cosmetic talc products caused cancer

Johnson & Johnson JNJ, +1.05% stock rose nearly 3% in the extended session Tuesday after the company said that its subsidiary LTL Management LLC has re-filed for voluntary Chapter 11 bankruptcy protection in order to obtain the approval of a reorganization plan that will “equitably and efficiently resolve all claims arising from cosmetic talc litigation” against the company. Johnson & Johnson said it has agreed to contribute up to $8.9 billion, payable over 25 years, to resolve “all the current and future talc claims.

Johnson & Johnson stock up nearly 3% after talc-litigation unit re-files for bankruptcy

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE:JNJ) (the Company) today announced that its subsidiary LTL Management LLC (LTL) has re-filed for voluntary Chapter 11 bankruptcy protection to obtain approval of a reorganization plan that will equitably and efficiently resolve all claims arising from cosmetic talc litigation against the Company and its affiliates in North America. To that end, the Company has agreed to contribute up to a present value of $8.

Johnson & Johnson Subsidiary LTL Management LLC (“LTL”) Re-Files for Voluntary Chapter 11 to Equitably Resolve All Current and Future Talc Claims

TRENTON, N.J.--(BUSINESS WIRE)--Cancer victims who are seeking to hold Johnson & Johnson (NYSE: JNJ) responsible after being exposed to cancer-causing talc in its Johnson's Baby Powder will be asking state courts and the judge in the federal talc multidistrict litigation to immediately resume civil court trials. “The bankruptcy that was rejected by the U.S.

Beasley Allen/Arnold & Itkin Law Firms: On Eve of J&J Bankruptcy Dismissal, Cancer Victims Prepare to Enter Civil Court System

Eli Lilly

Merck

Eli Lilly's promising diabetes drug Mounjaro could be an obesity-therapy blockbuster. Johnson & Johnson's consumer healthcare spinoff will make the company more profitable.

3 Top Healthcare Stocks to Buy for April

JNJ is a dividend king for having increased their dividend for 50+ consecutive years. At the end of the year, JNJ will be spinning off its consumer health segment into a separate public company called Kenvue.

Johnson & Johnson: A Huge Opportunity In A Blue-Chip Dividend King

AbbVie

Realty Income Corp

Mr. Valuation has been almost like a college professor for our team of analysts, always adhering to the timeless principles of the margin of safety. Mr. Valuation explains that the dividend received from a publicly traded company represents significant investment benefits.

3 Dividend Aristocrats That Generate Income For Life

Disney

Verizon

The Dow Jones Industrial Average vastly outperformed the Nasdaq Composite in 2022. The Dow's 30 components are generally profitable and time-tested, which makes them a smart choice for investors during a bear market.

3 Dow Stocks That Are Screaming Buys in April

Apple

Costco

Discover

W.W. Grainger

Kinder Morgan

Procter & Gamble

Sysco

Dividends are the foundation of our goal to reach financial freedom. We continuously invest in dividend growth stocks to grow our passive income.

9 Upcoming Dividend Increases In April 2023

The Abiomed acquisition enhances JNJ's positioning in one of the most lucrative markets around and could be earnings accretive next year. The dividend narrative is hugely compelling and looks resilient enough, despite the weakening of some financial metrics.

6 Reasons To Consider Johnson & Johnson Stock

Investors have been abandoning Johnson & Johnson stock in droves as mounting legal issues and a shift towards risk-on sectors have exacerbated negative sentiment surrounding the company. Despite growing legal uncertainties and heightened scrutiny, we believe Johnson & Johnson is well-equipped to fulfill its obligations and emerge from this challenge even stronger.

Johnson & Johnson: Don't Run As It's Time To Be Greedy

Chevron

Lockheed Martin

PepsiCo

Texas Instruments

In this article, we start with a discussion of the importance of inflation protection (in light of current developments) and things to consider before researching individual stocks. I then present five dividend stocks with stellar balance sheets, wide-moat business models, consistent and high dividend growth, and the unique ability to offset high inflation.

Surviving Inflation: 5 Perfect Dividend Stocks To Get The Job Done

Amgen

Coca-Cola

Johnson & Johnson offers investors a 2.9% yield now and a 2-for-1 deal later this year. Amgen offers a 3.5% yield fueled by high-margin pharmaceutical sales.

3 Dow Stocks With Above-Average Dividends Yields to Buy in April

CVS Health

Medtronic

Shares of CVS Health have been beaten down in response to lower COVID-related revenue, but this is only a temporary setback. Medtronic shares offer an above-average dividend yield, and its payout has risen for 45 consecutive years.

3 Top S&P 500 Stocks Near 52-Week Lows That Look Like Bargains Now

Paramount Global

U.S. Bancorp

Investors closely follow the Oracle of Omaha's trading activity because of his phenomenal track record. Three Buffett stocks with clear-cut competitive advantages are ripe for the picking by opportunistic investors.

3 Warren Buffett Stocks That Are No-Brainer Buys in April

Johnson & Johnson's talc lawsuit issues continue. Looming loss of exclusivity on JNJ's top drug can drag revenues.

Johnson & Johnson: Negative Alpha Likely Ahead

Moderna

J&J is dropping out of the adult RSV vaccine race. This leaves the market to Moderna, Pfizer, and GSK; all three are close to reaching commercialization with their vaccine candidates.

Could This Move by Johnson & Johnson Equal Billions for Moderna?

Axsome Therapeutics

Pfizer

Axsome Therapeutics has multiple catalysts on the way. Johnson & Johnson is a bargain with its improving growth prospects.

News for Johnson & Johnson Stock (JNJ)